Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
Funding has been made available which will enable new research to take place into a possible link between manganese exposure ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
A new study from the University of Oxford demonstrates how clinicians could use data to predict the risk of falls in people ...
in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that may slow progression of Parkinson’s disease by targeting underlying ...
Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including ...